The increase in the pathway activity of TNF-α and TGF-β was associated with increased stem cell quiescence and thereby TKI resistance in poor responder CML patients (patients not achieving MMR) [88]. This evidence concerns the gene TNF and chronic myelogenous leukemia, BCR-ABL1 positive.